Skip to main content
TipRanks
Go Ultimate75% OFF

Krystal Biotech (4KB) Q3 2026 Earnings Report

1 Followers

DE:4KB Q3 2026 EPS Results

Actual EPS
EUR 1.87
Consensus EPS
EUR 1.63
Beat/Miss
Beat by +EUR 0.24
One Year Ago EPS
EUR 2.43

DE:4KB Q3 2026 Revenue Results

Actual Revenue
EUR 116.13M
Expected Revenue
EUR 114.70M
Beat/Miss
Beat by +EUR 1.43M
YoY Revenue Growth
+30.21%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/02/2026
Time
Before Open
Conference Call
Monday, November 2, 2026
DE:4KB Upcoming Earnings

Krystal Biotech's next earnings date is estimated for March 1, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:4KB Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 02, 2026|% Change Since:-1.81%|
Earnings Call Sentiment|Positive

The call was strongly positive, supported by 30% VYJUVEK revenue growth, substantial cash and profitability, continued US and international commercial expansion, encouraging Gorlin syndrome data, and broad pipeline progress. The main negatives were lower gross margin and year-over-year net income, along with delayed or slower enrollment and readouts in several clinical programs. Management nevertheless characterized the studies as progressing well and maintained multiple 2027 development milestones.

Company Guidance

Krystal revised full year non GAAP R&D and SG&A guidance to $155 million to $165 million from prior guidance of $175 million to $195 million; it expects to deploy a share repurchase program of up to $400 million over the next 2 years, launch VYJUVEK in Italy in early 27, receive a Spain pricing decision before the end of the year with a potential launch next year, and share HHD data before year end. For KB408, it expects the last-patient, last-visit in February 2027 with top line results shortly thereafter and said ocular DEB will come ahead of NK; for KB801, it now expects to complete enrollment and report top-line results in 2027. For KB407, it expects to enroll and dose 3 additional patients before the year end, report interim study results in the first half of 27, and start a 2027 registrational study; for inhaled KB707, it expects to enroll and dose 70 patients at the selected regimen by mid 27.

  • Strong Q3 Revenue, Profitability, and LiquidityThird-quarter VYJUVEK revenue was $127.3 million, up 30% from the same period last year. Reported diluted earnings were $2.05 per share, and the company ended September with $1.2 billion in cash and investments.
  • VYJUVEK Reaches $1.1 Billion in Cumulative RevenueKrystal has generated approximately $1.1 billion in VYJUVEK revenue since launch, reflecting continued patient treatment and physician adoption.
  • US Commercial ExpansionUS net revenue was $95.3 million in the third quarter. The company has secured more than 760 reimbursement approvals nationwide and added over 80 new prescribers during the quarter.
  • Greater Flexibility in US AdministrationApproximately 80% of US patients now self-administer VYJUVEK, allowing patients and caregivers to incorporate treatment into their wound-care routines at home.
  • International Revenue and Market Access ProgressVYJUVEK international revenue reached $32 million in the third quarter. Pricing negotiations in Germany and Italy have concluded, Japan pricing has been secured, and Italy is expected to launch VYJUVEK in early 27. Spain pricing discussions are progressing, with a decision expected before the end of the year.
  • Expansion of Treatment Access in Germany and FranceMore than 20 German centers have initiated patients on VYJUVEK, up approximately 15% from the prior quarter. In France, the company completed the first home administration through the retrocession pathway and is working to extend the approach to additional eligible patients and centers.
  • Encouraging Gorlin Syndrome ResultsIn a pilot study of 3 adult Gorlin syndrome patients receiving 6 doses over 14 weeks, more than 80% of assessed lesions regressed, more than half of all lesions regressed by over 50%, and roughly 10% of assessed tumors shrank by at least 90%. Regression was observed in both injected and non-injected lesions, and complete clearance was confirmed histologically in 1 injected tumor from each patient.
  • Progress in Hailey-Hailey Disease ProgramThe company completed enrollment of 5 patients in the repeat-dose HHD-01 study and expects to provide a data update before year end. Part A of the investigator-based clinical scale validation is complete, while Part B is expected to be nearly complete.
  • Ocular DEB Study Advances Toward Readout and FilingKrystal enrolled 3 additional patients in the registrational DEB-I study, including a 1-year-old child to generate evidence supporting potential treatment of corneal abrasions from birth. The last-patient, last-visit is expected in February 2027, with top-line results shortly thereafter. The company stated that CMC requirements are complete and that it expects to be ready to file the BLA after database lock and data analysis.
  • Expansion of NK Clinical Trial InfrastructureThe KB801 NK study has activated 22 sites in the United States, with additional US sites and sites in France, Spain, and the United Kingdom being advanced. The company also plans to expand across Europe and Eastern Europe.
  • CF and AATD Programs Continue to AdvanceFor KB407 in cystic fibrosis, 3 patients are currently receiving repeat dosing and 3 additional patients are expected to be enrolled and dosed before year end. Interim results are anticipated in the first half of 27, and the program has been selected for the FDA complex innovative design meeting program, supporting a planned 2027 registrational study start. The company also remains on track to report interim data next year for its repeat-dose AATD study, and successful gene delivery has been confirmed by biopsies for both programs.
  • Progress in Inhaled Oncology ProgramThe inhaled KB707 program is enrolling patients with advanced NSCLC in the KYANITE-1 expansion cohort evaluating KB707 plus chemotherapy. Dose optimization was completed in 10 patients, and the company expects to enroll and dose 70 patients at the selected regimen by mid-27.
  • Share Repurchase AuthorizationThe board authorized a share repurchase program of up to $400 million, expected to be deployed over the next 2 years.
  • Lower Full-Year Non-GAAP Operating Expense GuidanceThe company revised full-year non-GAAP R&D and SG&A guidance to $155 million to $165 million from prior guidance of $175 million to $195 million.
  • Lower General and Administrative ExpensesThird-quarter G&A expenses were $33.7 million compared with $37.6 million in the prior-year quarter, a $3.8 million decrease primarily due to insurance proceeds reimbursing previously incurred legal costs and lower period-over-period legal costs, professional service fees, and marketing costs.

DE:4KB Earnings History

DE:4KB earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 01, 20272026 (Q4)1.86-1.55――
Nov 02, 20262026 (Q3)1.631.872.43-22.93% (-0.56)
Aug 03, 20262026 (Q2)1.551.631.1838.76% (+0.46)
May 04, 20262026 (Q1)1.361.671.0952.50% (+0.57)
Feb 17, 20262025 (Q4)1.401.551.3911.84% (+0.16)
Nov 03, 20252025 (Q3)0.992.430.83192.31% (+1.60)
Aug 04, 20252025 (Q2)1.081.180.48143.40% (+0.69)
May 06, 20252025 (Q1)1.301.090.033900.00% (+1.07)
Feb 19, 20252024 (Q4)1.081.390.27406.67% (+1.11)
Nov 04, 20242024 (Q3)0.910.832.54-67.38% (-1.71)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed